Please enable JavaScript.
Coggle requires JavaScript to display documents.
AML - Coggle Diagram
AML
APL
tx
low/intermediate risk ATRA+arsenic
HR
ATRA/arsenic + AraC or Gemtuzumab ozogamicin
t15;17
PML-RARA
immunophenotype
CD33+++ HLA-DR-
DIC
high early mortality due to bleeding
chemo agents
Ara C
kidney excretion
anthracyclines
topoisomerase II inhibitors
calculate risk
based on genomics
impacts tx
favorable risk
no need for alloSCT
high dose cytarabine as consolidation
can cause cerebellar neurotoxicity
intermediate/HR
induction to achieve remission + alloSCT as consolidation
intensive induction chemotx